<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02426879</url>
  </required_header>
  <id_info>
    <org_study_id>NL48231.041.14</org_study_id>
    <nct_id>NCT02426879</nct_id>
  </id_info>
  <brief_title>Esophagectomy for Patients With Esophageal Cancer and Cervical Lymph Node Metastases</brief_title>
  <acronym>Node</acronym>
  <official_title>Esophagectomy for Patients With Esophageal Cancer and Cervical Lymph Node Metastases Node Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no world-wide consensus on the oncological benefit versus increased morbidity
      associated with three field lymphadenectomy in patients with esophageal cancer and cervical
      lymph node metastases. In Asian countries, esophagectomy is commonly combined with a three
      field lymphadenectomy, including resection of cervical, thoracic and abdominal lymph nodes.
      However, in Western countries patients with cervical lymph node metastases are generally
      precluded from curative treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To assess the safety and feasibility of curative esophagectomy combined with three
      field lymphadenectomy after chemo-radiation in Western patients with resectable thoracic
      esophageal carcinoma and cervical lymph node metastases. Secondary objective is to determine
      the effect on survival and recurrence.

      Study design: Mono centre prospective phase II single-arm feasibility study. Study
      population: Western patients diagnosed with resectable (cT1-4a, N1-3) intra thoracic
      esophageal carcinoma with histological or cytological proven cervical lymph node metastases
      in level III and/ or IV.

      Intervention: Transthoracic esophageal resection combined with three field lymphadenectomy
      after neoadjuvant chemo-radiation.

      Main study parameters/ endpoints: Primary outcome is the percentage of overall surgical
      complications grade 3b and higher as stated by the Modified Clavien-Dindo classification.
      Secondary outcomes are mortality, operation related events and postoperative recovery,
      including quality of life, disease free survival, overall survival and if applicable the
      location of recurrent disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2015</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured by the percentage of overall postoperative complications grade 3b and higher as stated by the modified Clavien-Dindo classification (MCDC)</measure>
    <time_frame>5 years</time_frame>
    <description>Safety is measured by the percentage of overall postoperative complications grade 3b and higher as stated by the modified Clavien-Dindo classification (MCDC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>5 years</time_frame>
    <description>in-hospital mortality and 30- and 60 day mortality (absolute numbers/ percentages)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>5 years</time_frame>
    <description>5 year overall- and disease free survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life measured by questionnaires (EORTC-QLQ_C30 and EORTC-QLQ_Oes18)</measure>
    <time_frame>10 years</time_frame>
    <description>QoL is measured by questionnaires (EORTC-QLQ_C30 and EORTC-QLQ_Oes18)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operation related events 1</measure>
    <time_frame>5 years</time_frame>
    <description>duration of surgery (minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operation related events 2</measure>
    <time_frame>5 years</time_frame>
    <description>reason for prolongation of surgery if applicable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operation related events 3</measure>
    <time_frame>5 years</time_frame>
    <description>unexpected events/ complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operation related events 4</measure>
    <time_frame>5 years</time_frame>
    <description>bloodloss (ml) reason for conversion if applicable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operation related events 5</measure>
    <time_frame>5 years</time_frame>
    <description>reason for conversion if applicable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative recovery</measure>
    <time_frame>5 years</time_frame>
    <description>duration of intubation (days), length of ICU/ MCU stay(days), length of hospital stay (days),</description>
  </secondary_outcome>
  <other_outcome>
    <measure>pathology results 1</measure>
    <time_frame>5 years</time_frame>
    <description>pTNM stage</description>
  </other_outcome>
  <other_outcome>
    <measure>pathology results 2</measure>
    <time_frame>5 years</time_frame>
    <description>site of tumour</description>
  </other_outcome>
  <other_outcome>
    <measure>pathology results 3</measure>
    <time_frame>5 years</time_frame>
    <description>length of tumour</description>
  </other_outcome>
  <other_outcome>
    <measure>pathology results 4</measure>
    <time_frame>5 years</time_frame>
    <description>type of tumour</description>
  </other_outcome>
  <other_outcome>
    <measure>pathology results 5</measure>
    <time_frame>5 years</time_frame>
    <description>gradation of tumour</description>
  </other_outcome>
  <other_outcome>
    <measure>pathology results 6</measure>
    <time_frame>5 years</time_frame>
    <description>margins of resection (R0, R1, R2)</description>
  </other_outcome>
  <other_outcome>
    <measure>pathology results 7</measure>
    <time_frame>5 years</time_frame>
    <description>mandard score</description>
  </other_outcome>
  <other_outcome>
    <measure>pathology results 8</measure>
    <time_frame>5 years</time_frame>
    <description>lymphnode status</description>
  </other_outcome>
  <other_outcome>
    <measure>pathology results 9</measure>
    <time_frame>5 years</time_frame>
    <description>vaso-invasion</description>
  </other_outcome>
  <other_outcome>
    <measure>pathology results 10</measure>
    <time_frame>5 years</time_frame>
    <description>perineural growth</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cancer</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Adenocarcinoma</condition>
  <condition>Malignancy</condition>
  <arm_group>
    <arm_group_label>surgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>esophagectomy with three-field lymphnode dissection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>esophagectomy with three-field lymphnode dissection</intervention_name>
    <description>robot assisted thoraco-laparoscopic esophagectomy with three-field lymphnode dissection</description>
    <arm_group_label>surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven squamous cell carcinoma or adenocarcinoma of the esophagus.

          -  Surgical resectable carcinoma (T1-4a, N1-3) (table 1)

          -  Histologically/ cytologically proven resectable cervical lymph node metastases level
             III and/ or IV

          -  Age â‰¥ 18

          -  European Clinical Oncology Group (ECOG) performance status 0,1 or 2

          -  Written informed consent

        Exclusion Criteria:

          -  Distant metastases

          -  Esophageal carcinoma &lt; 3 cm beneath UES

          -  Carcinoma of the gastro-esophageal junction (GEJ) with major tumor in the gastric
             cardia (Siewert III)

          -  Former radiotherapy or chemotherapy for esophageal carcinoma

          -  Former radiotherapy precluding radiotherapy according the CROSS protocol

          -  Inadequate pulmonary function disabling transthoracic resection

          -  &gt;10% loss of weight in the last six months

          -  Previous neck dissection

          -  New York heart association class III/IV and no history of active angina. Patients with
             a history of significant ventricular arrhythmia requiring medication or congestive
             heart failure. History of 2nd or 3rd degree heart blocks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard V Hillegersberg, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvia van der Horst, Drs</last_name>
    <phone>088-7558074</phone>
    <email>shorst2@umcutrecht.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard van Hillegersberg, Propf Dr</last_name>
      <phone>+3188-7558074</phone>
      <email>r.vanhillegersberg@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Sylvia van der Horst, Drs</last_name>
      <phone>+3188-7558074</phone>
      <email>shorst2@umcutrecht.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Richard van Hillegersberg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jelle P. Ruurda, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>sylvia van der Horst, Drs</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>April 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2015</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Richard van Hillegersberg</investigator_full_name>
    <investigator_title>prof Dr</investigator_title>
  </responsible_party>
  <keyword>three-field lymphadenectomy</keyword>
  <keyword>cervical metastases</keyword>
  <keyword>esophagectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

